• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

    6/7/22 7:30:00 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INZY alert in real time by email

    BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer. Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex, brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations.

    "It is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme's clinical development and regulatory strategy," said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. "Kurt's experience across the entirety of the drug development process will be invaluable as we advance INZ-701 in our ongoing Phase 1/2 clinical trials in patients with ENPP1 Deficiency and ABCC6 Deficiency and prepare for our later-stage studies."

    "ENPP1 Deficiency and ABCC6 Deficiency represent two devastating rare diseases for which there are currently no approved therapies," said Dr. Gunter. "I firmly believe that INZ-701 could serve as a much-needed intervention for patients suffering from these highly underserved areas, and I look forward to contributing to Inozyme's mission of addressing these urgent unmet needs."

    Prior to Athenex, Dr. Gunter served as chief medical officer at Kuur Therapeutics (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments. He also previously held positions of increasing responsibility at Hospira, Inc., including vice president, clinical development, and global medical director for hematology-oncology. Before Hospira, Dr. Gunter held positions at Zymequest, ViaCell, and Transkaryotic Therapies, Inc. While at Transkaryotic Therapies, Inc., he played an integral role in the global regulatory strategy for Replagal, an enzyme replacement therapy (ERT) approved for Fabry disease. He also previously served as president of the International Society for Cellular Therapy (ISCT), where he played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies.

    Prior to his biotech career, Dr. Gunter worked at the U.S. Food and Drug Administration (FDA) as a medical officer in the Center for Biologics and was appointed acting deputy director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research. He also served for five years on the FDA's Cellular, Tissue and Gene Therapies Advisory Committee.

    Dr. Gunter earned his M.D. from the University of Kansas School of Medicine, and also has a B.S. in Biological Sciences, with Distinction, from Stanford University. His postdoctoral training included Johns Hopkins University and the U.S. National Institutes of Health.

    About Inozyme Pharma

    Inozyme Pharma, Inc. (NASDAQ:INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

    Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

    Cautionary Note Regarding Forward-Looking Statements

    Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our clinical trials, and the potential benefits of INZ-701. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to initiate and conduct its ongoing and planned Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

    Contacts

    Investors:

    Inozyme Pharma

    Stefan Riley, Director of Investor Relations

    857-330-8871

    [email protected]        

    Media:

    SmithSolve

    Matt Pera

    973-886-9150

    [email protected]



    Primary Logo

    Get the next $INZY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INZY

    DatePrice TargetRatingAnalyst
    12/12/2024$26.00Outperform
    Raymond James
    9/12/2024$16.00Buy
    Stifel
    8/13/2024$16.00 → $17.00Buy
    Jefferies
    5/30/2024$14.00Overweight
    Wells Fargo
    3/23/2023$4.50 → $6.00Hold → Buy
    Jefferies
    5/26/2022$5.00Hold
    Jefferies
    2/7/2022$33.00Buy
    HC Wainwright & Co.
    11/29/2021$23.00Buy
    Needham
    More analyst ratings

    $INZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:16:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Winton Matthew closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:08:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bolte Axel closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:07:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

      BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the "Acquisition") by BioMarin Pharmaceutical Inc. ("BioMarin"). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitl

      6/20/25 5:00:00 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    SEC Filings

    See more
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:26 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:16 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Inozyme Pharma Inc.

      25-NSE - Inozyme Pharma, Inc. (0001693011) (Subject)

      7/1/25 9:54:57 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Inozyme Pharma with a new price target

      Raymond James initiated coverage of Inozyme Pharma with a rating of Outperform and set a new price target of $26.00

      12/12/24 8:10:19 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Inozyme Pharma with a new price target

      Stifel initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $16.00

      9/12/24 7:42:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Inozyme Pharma with a new price target

      Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

      8/13/24 7:33:31 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Leadership Updates

    Live Leadership Updates

    See more
    • Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financi

      5/14/25 7:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical c

      11/5/24 8:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

      BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry. "It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for ou

      10/7/24 8:30:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Financials

    Live finance-specific insights

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

      - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage

      4/8/24 6:30:35 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      12/9/24 4:14:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inozyme Pharma Inc.

      SC 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

      11/14/24 12:19:37 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      10/24/24 2:02:10 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care